May 234BIO Capital Portfolio Company Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease
Jan 25, 20214BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery
